Outcome of advanced stage (III/IV) intermediate-risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: a Children's Oncology Group report

被引：0

作者：

Goldman, S. ^{[1
]}

Smith, L. ^{[2
]}

Anderson, J. R. ^{[2
]}

Perkins, S. ^{[3
]}

Harrison, L. ^{[4
]}

Shiramizu, B. ^{[9
]}

Sanger, W. ^{[10
]}

Barth, M. ^{[11
]}

Cairo, M. S. ^{[4
,5
,6
,7
,8
]}

机构：

[1] Med City Childrens Hosp, Div Pediat Hematol Oncol, Dallas, TX USA

[2] Univ Nebraska, Coll Publ Hlth, Dept Biostat, Omaha, NE 68182 USA

[3] Univ Utah, Dept Pathol, Salt Lake City, UT USA

[4] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA

[5] New York Med Coll, Dept Med, Valhalla, NY 10595 USA

[6] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA

[7] New York Med Coll, Dept Microbiol, Valhalla, NY 10595 USA

[8] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA

[9] Univ Hawaii, Div Pediat Hematol Oncol, Honolulu, HI 96822 USA

[10] Univ Nebraska Med Ctr, Dept Cytogenet, Omaha, NE USA

[11] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：24 / 24

页数：1

共 50 条

[31] Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: A report from the Children's Oncology Group [J].

Frazer, J. Kimble ;

Goldman, Stanton ;

Smith, Lynette ;

Harrison, Lauren ;

Perkins, Sherrie L. ;

Cairo, Mitchell S. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[32] Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group [J].

Oberoi, Sapna ;

Qumseya, Amria ;

Xue, Wei ;

Harrison, Douglas J. ;

Rudzinski, Erin R. ;

Wolden, Suzanne L. ;

Dasgupta, Roshni ;

Venkatramani, Rajkumar ;

Gupta, Abha A. .

PEDIATRIC BLOOD & CANCER, 2023, 70 (09)

[33] Improved outcomes in CNS-positive pediatric Burkitt lymphoma/leukemia using rituximab plus FAB group C1 chemotherapy without CNS radiation: a Children's Oncology Group report [J].

Frazer, J. K. ;

Goldman, S. C. ;

Smith, L. ;

Harrison, L. ;

Perkins, S. L. ;

Cairo, M. S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 :3-3

[34] Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [J].

Hawkins, Douglas S. ;

Chi, Yueh-Yun ;

Anderson, James R. ;

Tian, Jing ;

Arndt, Carola A. S. ;

Bomgaars, Lisa ;

Donaldson, Sarah S. ;

Hayes-Jordan, Andrea ;

Mascarenhas, Leo ;

McCarville, Mary Beth ;

McCune, Jeannine S. ;

McCowage, Geoff ;

Million, Lynn ;

Morris, Carol D. ;

Parham, David M. ;

Rodeberg, David A. ;

Rudzinski, Erin R. ;

Shnorhavorian, Margarett ;

Spunt, Sheri L. ;

Skapek, Stephen X. ;

Teot, Lisa A. ;

Wolden, Suzanne ;

Yock, Torunn I. ;

Meyer, William H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (27) :2770-+

[35] Preliminary results of a reduced burden of therapy trial by incorporation of rituximab and intrathecal liposomal cytarabine in children, adolescents and young adults with intermediate (FAB Group B) and high risk (FAB Group C) mature B-cell lymphoma/leukemia. [J].

Goldman, Stanton ;

Barth, Matthew John ;

Oesterheld, Javier E. ;

Heym, Kenneth ;

Harrison, Lauren ;

Nickerson, Berkley ;

El-Mallawany, Nader ;

Hochberg, Jessica ;

Cairo, Mitchell S. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[36] Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the children's oncology group [J].

Russell, Heidi, V ;

Chi, Yueh-Yun ;

Okcu, M. Fatih ;

Bernhardt, M. Brooke ;

Rodriguez-Galindo, Carlos ;

Gupta, Abha A. ;

Hawkins, Douglas S. .

CANCER, 2022, 128 (02) :317-325

[37] Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group [J].

Shaikh, Furqan ;

Cullen, John W. ;

Olson, Thomas A. ;

Pashankar, Farzana ;

Malogolowkin, Marcio H. ;

Amatruda, James F. ;

Villaluna, Doojduen ;

Krailo, Mark ;

Billmire, Deborah F. ;

Rescorla, Frederick J. ;

Egler, Rachel A. ;

Dicken, Bryan J. ;

Ross, Jonathan H. ;

Schlatter, Marc ;

Rodriguez-Galindo, Carlos ;

Frazier, A. Lindsay .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (11) :1203-1210

[38] Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803-A Report From the Children's Oncology Group [J].

Minn, A. Yuriko ;

Lyden, Elizabeth R. ;

Anderson, James R. ;

Million, Lynn ;

Arndt, Carola A. ;

Brown, Kenneth ;

Hawkins, Douglas S. ;

Donaldson, Sarah S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4228-4232

[39] Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial [J].

Cairo, M. S. ;

Sposto, R. ;

Gerrard, M. ;

Waxman, I. ;

Goldman, S. ;

Auperin, A. ;

Pinkerton, R. ;

Raphael, M. ;

McCarthy, K. ;

Perkins, S. L. ;

Patte, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

[40] Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report. [J].

Shiramizu, B. ;

Goldman, S. ;

Kusao, I. ;

Agsalda, M. ;

Lynch, J. C. ;

Harrison, L. ;

Gross, T. G. ;

Sanger, W. ;

Perkins, S. L. ;

Cairo, M. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →